Oxford Asset Management’s Dicerna Pharmaceuticals, Inc. DRNA Stock Holding History

Oxford Asset Management’s Portfolio DRNA Stock Details DRNA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q1	–	Sell	-57,730	Closed	-$1.27M	–	1579
2019 Q4	$1.27M	Buy	+57,730	New	+$1.16M	0.04%	713
2018 Q4	–	Sell	-49,661	Closed	-$761K	–	2216
2018 Q3	$761K	Buy	49,661 +5,098	+11%	+$74.2K	0.02%	1135
2018 Q2	$539K	Sell	44,563 -144,731	-76%	-$1.82M	0.01%	1314
2018 Q1	$1.81M	Buy	189,294 +136,132	+256%	+$1.47M	0.04%	629
2017 Q4	$498K	Buy	+53,162	New	+$391K	0.01%	1180
2016 Q4	–	Sell	-59,006	Closed	-$347K	–	908
2016 Q3	$347K	Sell	59,006 -227,407	-79%	-$797K	0.01%	653
2016 Q2	$859K	Buy	286,413 +149,560	+109%	+$614K	0.03%	513
2016 Q1	$734K	Buy	136,853 +120,260	+725%	+$759K	0.02%	543
2015 Q4	$198K	Buy	+16,593	New	+$190K	﹤0.01%	798

Other funds holding DRNA

RTW Investments New York $10B AUM 135.35% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

BCLSI

Bain Capital Life Sciences Investors Boston, Massachusetts $1.11B AUM 171.34% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

EAM

Eagle Asset Management St Petersburg, Florida $19.6B AUM 41.58% 1-Year Est. Return

Oxford Asset Management's DRNA Position: Q1 2020 in Review

Oxford Asset Management sold out of Dicerna Pharmaceuticals, Inc. (DRNA) in Q1 2020, closing a stake of 57,730 shares — an estimated $1.27M sold.

Oxford Asset Management first reported a position in DRNA in Q4 2015 and held it in 9 quarters. The position peaked at $1.81M in Q1 2018. 144 funds tracked by Wall St. Rank hold DRNA as of Q1 2020.

Oxford Asset Management reported no remaining Dicerna Pharmaceuticals, Inc. position as of Q1 2020 after selling out during the quarter.
Oxford Asset Management sold 57,730 Dicerna Pharmaceuticals, Inc. shares in Q1 2020, an estimated $1.27M.
Oxford Asset Management first reported a position in Dicerna Pharmaceuticals, Inc. in Q4 2015 and held it in 9 quarters.
Oxford Asset Management's Dicerna Pharmaceuticals, Inc. position peaked at $1.81M in Q1 2018.
144 funds tracked by Wall St. Rank held Dicerna Pharmaceuticals, Inc. as of Q1 2020.

Based on Oxford Asset Management's 13F filing for Q1 2020, filed 15 May 2020.